Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence (CAMP)

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
New York State Psychiatric Institute
ClinicalTrials.gov Identifier:
NCT00553319
First received: November 2, 2007
Last updated: August 20, 2014
Last verified: August 2014

November 2, 2007
August 20, 2014
December 2007
July 2013   (final data collection date for primary outcome measure)
  • Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use [ Time Frame: weekly for 14 weeks of trial or for length of participation ] [ Designated as safety issue: No ]
    Each week after randomization was scored dichotomously as cocaine positive or negative. Cocaine use was positive if any urine or self-report was positive. Cocaine use was negative if all urines (BE <300 ng/ml) and all self-report were negative. Weeks with no urine or no self-report were designated missing.
  • ADHD Symptoms Based on ADHD Rating Scale [ Time Frame: measured once per week for 14 weeks or length of study participation ] [ Designated as safety issue: No ]
    The proportion of subjects exhibiting >30% reduction of AISRS score at last enrollment week compared to week 0
  • cocaine urine toxicology results [ Time Frame: per visit ]
  • ADHD symptoms (based on AARS) [ Time Frame: weekly ]
Complete list of historical versions of study NCT00553319 on ClinicalTrials.gov Archive Site
Not Provided
ADHD symptoms (based on CGI) [ Time Frame: weekly ]
Not Provided
Not Provided
 
Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence
A Randomized, Double-Blind, Placebo-Controlled Study of Mixed Amphetamine Salts (Adderall-XR) for the Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) and Cocaine Dependence

The proposed protocol is a 3 group double-blind, placebo-controlled outpatient study of the safety and efficacy of Adderall-XR (ER-MAS) in the treatment of comorbid ADHD and cocaine dependence. Since this medication has independently shown promise in helping with ADHD and cocaine abuse, we are proposing that it may be successful in the treatment of comorbid ADHD and cocaine abuse. We plan to enroll 75 subjects in a 14-week trial. The primary objectives of the study are to determine the efficacy of ER-MAS in promoting cocaine abstinence and improvement in ADHD symptomology among cocaine-dependent patients with comorbid ADHD.

Specific Aim 1: To determine the efficacy of ER-MAS in promoting cocaine abstinence and ADHD improvement among comorbid ADHD and cocaine-dependent patients.

Primary Hypothesis: benzoylecgonine positive urine screens will decrease with greatest to least reductions from 80mg>60mg>PBO (placebo).

Hypothesis 2: ADHD-Rating Scale will decrease with greatest to least reductions from 80mg>60mg>PBO.

Specific Aim 2: To determine the effect of ER-MAS on improving general functioning and impulsivity among comorbid ADHD and cocaine-dependent patients.

Hypothesis 4: There will be greater improved CGI (clinical global impression scale) scores in participants receiving d-AMPH (d-amphetamine) compared to PBO.

Hypothesis 5: ER-MAS will decrease impulsivity as measured by several self-report (Barratts Impulsivity Scale) and behavioral measures (Card Sort, IMT (immediate memory task), DMT (delayed memory task), BART) compared to PBO.

This 14-week, three arm (two medication doses versus PBO), prospective, parallel groups, randomized PBO-controlled trial with a lead-in as well as medication run-up and run down weeks, will provide clear data on efficacy and safety for definitive Phase III trials, which if successful will lead to improved treatment for A-ADHD/S-SUD.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Adult Attention Deficit Hyperactivity Disorder
  • Cocaine Dependence
  • Drug: Placebo
    Placebo group
    Other Name: Placebo
  • Drug: Adderall-XR
    Adderall-XR 60mg/day
    Other Name: Extended-Release Mixed Amphetamine Salts (Adderall-XR)
  • Drug: Adderall-XR
    Adderall-XR 80mg/day
    Other Name: Extended-Release Mixed Amphetamine Salts (Adderall-XR)
  • Placebo Comparator: Placebo
    Placebo
    Intervention: Drug: Placebo
  • Experimental: Adderall-XR 60 mg
    Adderall-XR 60 mg
    Intervention: Drug: Adderall-XR
  • Experimental: Adderall-XR 80 mg
    Adderall-XR 80 mg
    Intervention: Drug: Adderall-XR
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
139
July 2013
July 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Men and women between the ages of 18-60 who meet DSM-IV criteria for current cocaine dependence and adult ADHD (DSM-IV-TR).
  2. Used cocaine at least four days in the past month
  3. Must have a Body Mass Index (BMI) > 18 kg/m2
  4. Alcohol Breathalyzer (BraC) at consent of < 0.04%
  5. Individuals must be capable of giving informed consent and capable of complying with study procedures.
  6. Women of child bearing age will be included in the study provided that they are not pregnant, based on the results of a blood pregnancy test drawn at the time of screening. They must also agree to use a method of contraception with proven efficacy and agree not to become pregnant during the study. To confirm this, blood pregnancy tests will be repeated monthly. Women will be provided a full explanation of the potential dangers of pregnancy while on the study medication. If a woman becomes pregnant, the study medication will be discontinued.

Exclusion Criteria:

  1. Meets DSM-IV-TR criteria for bipolar disorder, schizophrenia or any psychotic disorder other than transient psychosis due to drug abuse.
  2. Individuals with any current Axis I psychiatric disorder as defined by DSM-IV-TR supported by the SCID-I/P that in the investigator's judgment are unstable or would be disrupted by study medication or are likely to require pharmacotherapy during the study period.
  3. Individuals with current major depressive disorder.However,individuals who are currently stable on a psychotropic medication for three months with a HAM-D <14 may be included.
  4. Individuals physiologically dependent on any other drugs (excluding nicotine or cannabis) which require medical intervention.
  5. Individuals with current suicidal risk.
  6. Individuals with coronary vascular disease as indicated by history or suspected by abnormal ECG, cardiac symptoms, fainting, open-heart surgery and/or arrhythmia, and family history of ventricular tachycardia/sudden death.
  7. Unstable physical disorders which might make participation hazardous such as uncontrolled hypertension (SBP > 140, DBP> 90, or HR > 100 when sitting quietly), acute hepatitis (patients with chronic mildly elevated transaminases < 3x upper limit of normal are acceptable), or uncontrolled diabetes.
  8. Individuals with a history of seizures
  9. History of allergic reaction to candidate medication (amphetamine and/or ER-MAS).
  10. Women who are pregnant or nursing.
  11. History of failure to respond to a previous adequate trial of the candidate medication for cocaine dependence
  12. Individuals who are legally mandated (e.g., to avoid incarceration, monetary or other penalties, etc.) to participate in substance abuse treatment program
  13. History of glaucoma
  14. Individuals who report use of MAOI within 14 days of study start
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00553319
#5502/6569R., R01DA023652-01
Yes
New York State Psychiatric Institute
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)
Principal Investigator: Frances R Levin, MD Columbia University
Principal Investigator: John Grabowski University of Minnesota - Clinical and Translational Science Institute
New York State Psychiatric Institute
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP